Flovas 20mg 14 Tablets

Babies: It is not applicable. Lactating mothers: Flovas tablet is probably unsafe to use during breastfeeding.
Limited human data suggests that the drug may pass into breast milk and harm the baby. Pregnancy: Flovas tablets may be unsafe to use during pregnancy.
There are limited studies in humans; animal studies have shown harmful effects on the developing baby. Please consult your doctor.
Driving: Flovas tablet may decrease alertness, affects vision and may cause dizziness and sleep. Do not drive if these symptoms occur.
Alcohol: Caution is advised when consuming alcohol with flovas tablets. Please consult your doctor.
Kidney: Flovas tablets should be used with caution in patients with kidney disease. Dosage adjustment is required, and regular monitoring of kidney function may be required.
Seek doctor’s advice before using this medication Liver: Flovas tablet is probably unsafe to use in patients with liver disease and should be avoided. Please consult your doctor..

Tachycardia Allergic reaction Dry mouth Jaundice Urticarial.

It is a factor xa inhibitor, an anti-coagulant. It works by preventing clot formation in the body..

If you miss a dose, take it as soon as possible. If it is near the time of the next dose, then skip the missed dose.
Take the prescribed dose on your regular time daily. Don't double the dose to catch up with the missed dose..

• Take this medication after food at night time to get full benefits of it. • Care must be taken when cutting fingernails or vegetables because it may increase bleeding.
• Do not change the drug or dose of the drug without consulting the doctor. • Do not take any other medication without consulting your doctor.
• Do not stop taking the medication without talking to your doctor. • Inform your doctor if you are pregnant or intend to be a pregnant and breastfeeding mother.
• Inform your doctor if you are using any hiv medications. • Tell your doctor if you have any kidney or liver diseases..

Contraindicated • Flovas + Defibrotide: Concurrent use may lead to an increased risk of bleeding Major • Flovas + Abametapir: Concurrent use may lead to increased exposure of cyp3a4 substrate • Flovas + Capmatinib: Concurrent use of capmatinib and p-gp substrates may lead to the risk of increased adverse reactions • Flovas + Abciximab: Concurrent use may lead to an increased risk of bleeding • Flovas + Aceclofenac: Concurrent use may lead to an increased risk of bleeding • Flovas + Bivalirudin: Concurrent use may lead to an increased risk of bleeding • Flovas + Carbamazepine: Concurrent use may lead to decreased plasma concentrations of flovas.